A Monoclonal Antibody-Based Enzyme Immunoassay for Fibrin Degradation Products in Plasma

Summary

We have developed a sandwich-type enzyme immunoassay (EIA) for the quantitation of fibrin degradation products (FbDP) in plasma with a time-to-result of only 45 minutes.* The assay is based on the combination of the specificities of two monoclonal antibodies (FDP-14 and DD-13), developed in our institute. FDP-14, the capture antibody, binds both fibrinogen degradation products (FbgDP) and FbDP, but does not react with the parent fibrin(ogen) molecules. It has its epitope in the E-domain of the fibrinogen molecule on the Bβ-chain between amino acids 54-118. Antibody DD-13 was raised using D-dimer as antigen and is used as a tagging antibody, conjugated with horse-radish peroxidase. A strong positive reaction is obtained with a whole blood clot lysate (lysis induced by tissue-type plasminogen activator) which is used as a standard. The EIA does virtually not detect FbgDP i. e. purified fragments X, Y, or FbgDP generated in vitro in plasma by streptokinase treatment. This indicates that the assay is specific for fibrin degradation products.

We have successfully applied this assay to the plasma of patients with a variety of diseased states. In combination with the assay previously developed by us for FbgDP and for the total amount of FbgDP + FbDP (TDP) in plasma, we are now able to study the composition of TDP in patients plasma in terms of FbgDP and FbDP.

Keywords

Enzyme immunoassay - Fibrin degradation products - Plasma - Monoclonal antibodies

• References

• 1 Graeff H, Hafter R. Detection and relevance of crosslinked fibrin derivatives in blood. Sem Thromb Haemostas 1982; 8: 57-68
• 2 Francis CW, Marder VJ. A molecular model of plasmic degradation of crosslinked fibrin. Sem Thromb Haemostas 1982; 8: 25-35
• 3 Connaghan DG, Francis CW, Ryan DH, Marder VJ. Prevalenceand clinical implications of heparin-associated false positive tests forserum fibrin(ogen) degradation products. Am J Clin Pathol 1986; 86: 304-310
• 4 Gaffney PJ, Perry MJ. Unreliability of current serum fibrindegradation product (FDP) assays. Thromb Haemostas 1985; 53: 301-302
• 5 Marder VJ, Shulman NR. High molecular weight derivatives ofhuman fibrinogen produced by plasmin II Mechanism of theiranticoagulant activity. J Biol Chem 1969; 244: 2120-2124
• 6 Niewiarowski S, Stewart GJ, Marder VJ. Formation of highlyordered polymers from fibrinogen and fibrin degradation products. Biochim Biophys Acta 1970; 221: 326-341
• 7 Rylatt DB, Blake AS, Gottis LE, Massingham DA, Fletcher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, Wyatt D, Bundesen PG. An immunoassay for human D dimer using mono-clonal antibodies. Thromb Res 1983; 31: 767-778
• 8 Gaffney PJ, Creighton LJ, Harris R, Perry MJ. Monoclonalantibodies (MABS) to crosslinked fibrin fragments: their characterisa-tion and potential clinical use. In: Fibrinogen and its derivativesBiochemistry physiology and pathophysiology Proceedings of theFibrinogen WorkshopGieBen FRG 22-23 May 1986 Miiller-Berghaus G, Scheefers-Borchel U, Selmayr E, Henschen A. (Eds) Excerpta Medica Amsterdam; New York Oxford: pp 273-284
• 9 Koopman J, Haverkate F, Koppert P, Nieuwenhuizen W, Brommer EJ P, Van der Werf WG C. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal anti-body. J Lab Clin Med 1987; 109: 75-84
• 10 Koppert PW, Kuipers W, Hoegee-de Nobel B, Brommer EJ P, Koopman J, Nieuwenhuizen W. A quantitative enzyme immunoassayfor primary fibrinogenolysis products in plasma. Thromb Haemostas 1987; 57: 25-28
• 11 Koppert PW, Koopman J, Haverkate F, Nieuwenhuizen W. Produc-tion and characterization of a monoclonal antibody reactive with aspecific neoantigenic determinant (comprising Bp 54-118) in degrada-tion products of fibrin and of fibrinogen. Blood 1986; 68: 437-441
• 12 Van Ruijven-Vermeer IA M, Nieuwenhuizen W, Haverkate F, Timan T. A novel method for the rapid purification of human and ratfibrin(ogen) degradation products in high yields. Hoppe-Seyler’s ZPhysiol Chem 1979; 360: 633-637
• 13 Nieuwenhuizen W, Gravesen M. Anticoagulant and calcium-bindingproperties of high molecular weight derivatives of human fibrinogenproduced by plasmin (fragments X). Biochim Biophys Acta 1981; 668: 81-88
• 14 Nieuwenhuizen W, Voskuilen M, Hermans J. Anticoagulant andcalcium-binding properties of high molecular weight derivatives ofhuman fibrinogen (plasmin fragments Y). Biochim Biophys Acta 1982; 708: 313-316
• 15 Van Ruijven-Vermeer IA M, Nieuwenhuizen W. Purification of ratfibrinogen and its constituent chains. Biochem J 1978; 169: 653-658
• 16 Koppert PW, Huijsmans CM G, Nieuwenhuizen W. A monoclonalantibody specific for human fibrinogen fibrinopeptide A-containingfragments and not reacting with free fibrinopeptide A. Blood 1985; 66: 503-507
• 17 Radi J. Immunoglobulin levels and abnormalities in aging humans andmice. In: Immunological techniques applied to aging research Adler WH, Nor din AA. (eds) CRC Press Inc; Boca Raton USA: pp 122-139
• 18 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG_1?IgG_2aandIgG_2bimmunoglobulins from mouse serum using protein A-Sephar-ose. Immunochem 1978; 15: 429-436
• 19 Nieuwenhuizen W, Creighton LC, Gaffney PJ, Graeff H, Hafter R, Hoegee-de Nobel B, Miiller-Berghaus G, Scheefers-Borchel U, Thurmayer R, Davies JA, Duckert F, Jespersen J, Matthias FR, Prentice CR M, Preston FE, Samama MM. A double blindcomparative study of six monoclonal antibody-based plasma assays forfibrinogen derivatives. In: Fibrinogen 2 Biochemistry Physiology andClinical relevance pp 181-186 Elsevier Science Publishers Amster-dam 1987;
• 20 Scheefers-Borchel U, Miiller-Berghaus G, Fuhge P, Eberle R, Heim-burger N. Discrimination between fibrin and fibrinogen by a mono-clonal antibody against a synthetic peptide. Proc Natl Acad Sci USA 1985; 82: 7091-7095
• 21 Kluft C, McNeill A, Adgey AA J, Rijken DC, Nieuwenhuizen W, Cohen AF. A randomized dose ranging study of two-chain tissue-typeplasminogen activator (BW/t-PA) in myocardial infarction: In vitromonitoring. Thromb Haemostas. 1987 54. (Abstr 175)
• 22 Seifried E, Tanswell P, Rijken DC, Kluft C, Hoegee E, Nieuwenhuizen W. Fibrin degradation products are not specificmarkers for thrombolysis in myocardial infarction. Lancet 1987; 8554: 333-334